Obstructive Sleep Apnea Syndrome Is Less Frequent in Patients With Well-Controlled Acromegaly Treated With Somatostatin Analogues, Pegvisomant or in Combination

Herrmann, Burkhard L. LSF; Stalla, Günter K.; Laubner, Katharina; Bidlingmaier, Martin; Führer, Dagmar LSF

Background:
Obstructive sleep apnea (OSA) often occurs in patients with active acromegaly and improves after treatment. Less is known about the development of OSA in patients after a longer period of control treated with somatostatin analogues (SSA) and pegvisomant.
Methods:
Seventy-nine patients (12 females, 17 males; age 49 ± 14 years; body mass index 29.9 ± 5.4 kg/m2; IGF-1 184 ± 73 μg/L; disease duration 13 ± 8 years (mean ± standard deviation)) with wellcontrolled acromegaly treated with SSA (38%), pegvisomant (38%) or in combination (24%) who underwent ambulatory polygraphy were included in a prospective multicenter cross-sectional study.
Results:
Fourteen percent had OSA (range of apnea-hypopnea index (AHI) 5 - 15). Patients with OSA (AHI ≥ 5 vs. < 5) had a longer disease duration (16 ± 1 vs. 12 ± 8 years; P = 0.01) and were older (61 ± 9 vs. 47 ± 13 years; P = 0.037). The AHI of all patients correlated with age (P = 0.01; r = 0.44). No differences were seen in terms of BMI and Epworth sleepiness scale score. Previous transsphenoidal surgery and radiation had no impact of the detection of OSA. The duration of well-controlled acromegaly was 7 ± 3 years.
Conclusion:
OSA in patients with well-controlled acromegaly treated with SSA, pegvisomant or in combination is less frequent (14%) than previously described. Early treatment to reduce the active disease period should be aimed to prevent OSA.

Cite

Citation style:
Herrmann, B.L., Stalla, G.K., Laubner, K., Bidlingmaier, M., Führer, D., 2018. Obstructive Sleep Apnea Syndrome Is Less Frequent in Patients With Well-Controlled Acromegaly Treated With Somatostatin Analogues, Pegvisomant or in Combination. https://doi.org/10.14740/jem455w
Could not load citation form.

Rights

Use and reproduction:
This work may be used under a
CC BY-NC 4.0 LogoCreative Commons Attribution - NonCommercial 4.0 License (CC BY-NC 4.0)
.

Export